source
- Sanofi books over €1 billion impairment after ending eczema drug and halting two immunology programsSanofi disclosed that it will record more than €1.03 billion in impairment charges for the second quarter. The bulk of the charge stems from the decision to terminate development of an eczema trea…
- FDA advisory panel backs Replimune's melanoma therapy RP1, raising approval prospectsAdvisors to the U.S. Food and Drug Administration voted 10-3 in favor of Replimune's experimental melanoma treatment, RP1, despite lingering scientific concerns about the data presented. The panel…